Who are Ketalar's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SEVOFLURANE, Suprane, PROPOFOL, Diprivan, Amidate, Forane.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketamine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Ketalar — Competitive Intelligence Brief

Ketalar (ketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General Anesthetic. Area: Metabolic.

marketed General Anesthetic Glutamate [NMDA] receptor Metabolic Live · refreshed every 30 min

Target snapshot

Ketalar (ketamine) — Ph Health. Ketamine works by blocking the action of glutamate at the NMDA receptor, which is involved in pain perception and memory formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketalar TARGET	ketamine	Ph Health	marketed	General Anesthetic	Glutamate [NMDA] receptor	1970-01-01
SEVOFLURANE	SEVOFLURANE		marketed	General Anesthetic [EPC]		1995-01-01
Suprane	DESFLURANE	Baxter	marketed	General Anesthetic [EPC]	GABA-A receptor; anion channel	1992-01-01
PROPOFOL	PROPOFOL		marketed	General Anesthetic [EPC]		1989-01-01
Diprivan	Propofol	Fresenius Kabi	marketed	General anesthetic	GABA A receptors	1989-01-01
Amidate	ETOMIDATE	Pfizer	marketed	General Anesthetic [EPC]	Cytochrome P450 11B2, mitochondrial	1982-01-01
Forane	ISOFLURANE	Baxter	marketed	General Anesthetic [EPC]	5-hydroxytryptamine receptor 2B	1979-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General Anesthetic class)

Baxter · 1 drug in this class
Ph Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketalar — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab